La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Medigen Vaccine Biologics Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Leo Lee

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	1.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

We're Hopeful That Medigen Vaccine Biologics (GTSM:6547) Will Use Its Cash Wisely

Mar 31

Would Medigen Vaccine Biologics (GTSM:6547) Be Better Off With Less Debt?

Dec 15

AMMINISTRATORE DELEGATO

Leo Lee

less than a year

Mandato

Leo Lee is Chief Executive Officer of Medigen Vaccine Biologics Corporation.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Chia-Hsiu Lin	Director	less than a year	NT$322.00k	Nessun dato
Ming Cheng Chang	Chairman	9yrs	NT$322.00k	Nessun dato
Tsan-Chien Chen	Director	11.8yrs	Nessun dato	Nessun dato
Yao-Chi Li	Independent Director	6.3yrs	NT$312.00k	Nessun dato
Ming-Yi Wu	Independent Director	1.3yrs	Nessun dato	Nessun dato
Chin-Yen Chen	Representative Director	less than a year	Nessun dato	Nessun dato
Peng-Fei Su	Independent Director	less than a year	Nessun dato	Nessun dato

1.3yrs

Durata media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 6547 non è considerato esperto (durata media del mandato 1.2 anni), il che suggerisce un nuovo consiglio.

Medigen Vaccine Biologics Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Less than half of directors are independent

Medigen Vaccine Biologics Corporation, Annual General Meeting, Jun 13, 2024

Medigen Vaccine Biologics Corporation Approves the Election of Ming-Yi ,Wu as Independent Director and Member of Audit and Remuneration Committees

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Medigen Vaccine Biologics Corporation to Report Q2, 2024 Results on Aug 01, 2024

Less than half of directors are independent

Medigen Vaccine Biologics Corporation to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings released: NT$3.53 loss per share (vs NT$4.56 loss in FY 2022)

Medigen Vaccine Biologics Corporation, Annual General Meeting, Jun 13, 2024

First half 2023 earnings released: NT$1.61 loss per share (vs NT$1.41 loss in 1H 2022)

Medigen Vaccine Biologics Corporation Withdraws Covid-19 Vaccine Provisional Application and Update with Three-Dose Data for Further Review

Medigen Vaccine Biologics Corporation Approves the Election of Ming-Yi ,Wu as Independent Director and Member of Audit and Remuneration Committees

Medigen Vaccine Biologics Corporation Files New Drug Application of MVC EV71 Vaccine (Envacgen) to Drug Administration of Vietnam

Less than half of directors are independent

Less than half of directors are independent

Medigen Vaccine Biologics Corporation Announces Results of MVC COVID-19 Vaccine Phase 3 Clinical Trial in Thailand

Third quarter 2022 earnings released: NT$0.95 loss per share (vs NT$2.16 profit in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: NT$0.97 loss per share (vs NT$0.57 loss in 2Q 2021)

Now 20% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Now 20% undervalued after recent price drop

MVC File Provisional Approval Application of COVID-19 Vaccine to Therapeutic Goods Administration

First quarter 2022 earnings released: NT$0.66 loss per share (vs NT$0.74 loss in 1Q 2021)

Medigen Vaccine Biologics Corporation Announces Update on Clinical Development on MVC Covid-19 Vaccine

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Bluewillow Biologics and Medigen Vaccine Biologics Announce Positive Results for Intranasal Covid-19 Booster Candidate in Pre-Clinical Studies

Medigen Vaccine Biologics Corporation Files New Drug Application (NDA) of MVC Quadrivalent Influenza Vaccine to Taiwan Food and Drug Administration

Third quarter 2021 earnings released: EPS NT$3.20 (vs NT$0.98 loss in 3Q 2020)

Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation Announces Launch of Its Covid-19 Vaccine Mvc-Cov1901 Adjuvanted with Dynavax's Cpg 1018 Adjuvant

Second quarter 2021 earnings released: NT$0.84 loss per share (vs NT$0.93 loss in 2Q 2020)

First quarter 2021 earnings released: NT$0.74 loss per share (vs NT$0.75 loss in 1Q 2020)

We're Hopeful That Medigen Vaccine Biologics (GTSM:6547) Will Use Its Cash Wisely

New 90-day high: NT$112

Medigen Vaccine Biologics Corporation Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax's CpG 1018 Announces First Participant Dosed in Phase 2 Clinical Trial in Taiwan

Metronic Global Berhad Provides Update on Termination of MOA with Medigen Vaccine Biologics Corporation to Obtain Exclusive Distribution Rights for MVC’s COVID-19 Vaccine

New 90-day high: NT$110

Would Medigen Vaccine Biologics (GTSM:6547) Be Better Off With Less Debt?

New 90-day high: NT$107

Metronic Global Berhad Announces Memorandum of Agreement with Medigen Vaccine Biologics Corporation

Medigen Vaccine Biologics Corporation and BlueWillow Biologics, Inc. Partners to Develop Intranasal Vaccine for SARS-CoV-2

Medigen Vaccine Biologics Corporation COVID-19 Vaccine Combined with Dynavax Technologies Corporation CpG 1018 Adjuvant Receives Taiwan Government Subsidy with First Participant Dosed in Early October

New 90-day low: NT$89.40

AMMINISTRATORE DELEGATO

Mandato

Membri del Consiglio di amministrazione

Durata media